| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| [2] |
Huang A, Yang Y, Shi JY, et al. Mucinous adenocarcinoma: a unique clinicopathological subtype in colorectal cancer [J]. World J Gastrointest Surg, 2021, 13(12): 1567-1583.
|
| [3] |
Leopoldo S, Lorena B, Cinzia A, et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features [J]. Ann Surg Oncol, 2008, 15(5): 1429-1439.
|
| [4] |
Hugen N, van Beek JJ, de Wilt JH, et al. Insight into mucinous colorectal carcinoma: clues from etiology [J]. Ann Surg Oncol, 2014, 21(9): 2963-2970.
|
| [5] |
Kermanshahi TR, Magge D, Choudry H, et al. Mucinous and signet ring cell differentiation affect patterns of metastasis in colorectal carcinoma and influence survival [J]. Int J Surg Pathol, 2017, 25(2): 108-117.
|
| [6] |
Aiken T, Hu CY, Uppal A, et al. Peritoneal recurrence after resection for stage I-III colorectal cancer: a population analysis [J]. J Surg Oncol, 2023, 127(4): 678-687.
|
| [7] |
Zhang Y, Qin X, Chen W, et al. Risk factors for developing peritoneal metastases after curative surgery for colorectal cancer: a systematic review and meta-analysis [J]. Colorectal Dis, 2021, 23(11): 2846-2858.
|
| [8] |
Reynolds IS, Fichtner M, McNamara DA, et al. Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers [J]. Cancer Metastasis Rev, 2019, 38(1-2): 237-257.
|
| [9] |
Kufe DW. Mucins in cancer: function, prognosis and therapy [J]. Nat Rev Cancer, 2009, 9(12): 874-885.
|
| [10] |
Jonckheere N, Van Der Sluis M, Velghe A, et al. Transcriptional activation of the murine Muc5ac mucin gene in epithelial cancer cells by TGF-beta/Smad4 signalling pathway is potentiated by Sp1 [J]. Biochem J, 2004, 377(Pt 3): 797-808.
|
| [11] |
Jonckheere N, Vincent A, Franquet-Ansart H, et al. GATA-4/-6 and HNF-1/-4 families of transcription factors control the transcriptional regulation of the murine Muc5ac mucin during stomach development and in epithelial cancer cells [J]. Biochim Biophys Acta, 2012, 1819(8): 869-876.
|
| [12] |
Kocer B, Soran A, Erdogan S, et al. Expression of MUC5AC in colorectal carcinoma and relationship with prognosis [J]. Pathol Int, 2002, 52(7): 470-477.
|
| [13] |
Melis M, Hernandez J, Siegel EM, et al. Gene expression profiling of colorectal mucinous adenocarcinomas [J]. Dis Colon Rectum, 2010, 53(6): 936-943.
|
| [14] |
Reynolds IS, O'Connell E, Fichtner M, et al. Mucinous adenocarcinoma of the colon and rectum: a genomic analysis [J]. J Surg Oncol, 2019, 120(8): 1427-1435.
|
| [15] |
Reynolds IS, Thomas V, O'Connell E, et al. Mucinous adenocarcinoma of the rectum: a whole genome sequencing study [J]. Front Oncol, 2020, 10: 1682.
|
| [16] |
Tan X, Fang Q, Xu Y, et al. Construction and validation of prognostic model for colorectal mucinous adenocarcinoma patients and identification of a new prognosis related gene FAM174B [J]. Transl Cancer Res, 2024, 13(10): 5233-5246.
|
| [17] |
Yin QZ, Liu YJ, Zhang Q, et al. Overexpression of basonuclin zinc finger protein 2 in stromal cell is related to mesenchymal phenotype and immunosuppression of mucinous colorectal adenocarcinoma [J]. Int Immunopharmacol, 2024, 142(Pt B): 113184.
|
| [18] |
Elkhamisy FAA, Eesa AN, Elnady OM, et al. Reduced expression of SOX11 in colorectal adenocarcinoma is associated with mucinous and signet ring cell types, poor survival, and lower ALK expression [J]. Pathol Res Pract, 2024, 260: 155450.
|
| [19] |
Deng C, Zhong ME, Chen Y, et al. Proteomic profiling and functional characterization of serum-derived extracellular vesicles in the mucinous and non-mucinous colon adenocarcinoma [J]. J Cancer Res Clin Oncol, 2023, 149(11): 9285-9300.
|
| [20] |
Monno M, Ogiri M, Seishima R, et al. POFUT1 and PLAGL2 are characteristic markers of mucinous colorectal cancer associated with MUC2 expression [J]. Cell Biochem Funct, 2024, 42(2): e3989.
|
| [21] |
Sun Y, Lin Y, Deng Y, et al. Identification of proteins associated with treatment response of neoadjuvant chemoradiotherapy in rectal mucinous adenocarcinoma by co-expression network analysis based on proteomic analysis [J]. J Proteomics, 2022, 254: 104472.
|
| [22] |
Foda AAM, Alamer HA, Ikram N, et al. Expression of CD10 and CD15 in colorectal mucinous and signet ring adenocarcinomas and its relation to clinicopathological features and prognosis [J]. Cancer Biomark, 2022, 33(1): 143-150.
|
| [23] |
Triki M, Kallel R, Feki J, et al. Prognostic significance of E-cadherin and Cox2 expression in Tunisian patients with colorectal mucinous adenocarcinoma [J]. Ann Diagn Pathol, 2020, 49: 151624.
|
| [24] |
Zhang X, Zuo J, Wang L, et al. Identification of differentially expressed genes between mucinous adenocarcinoma and other adenocarcinoma of colorectal cancer using bioinformatics analysis [J]. J Int Med Res, 2020, 48(8): 300060520949036.
|
| [25] |
Shen P, Yang S, Sun H, et al. SCF/c-KIT signaling increased Mucin2 production by maintaining Atoh1 expression in mucinous colorectal adenocarcinoma [J]. Int J Mol Sci, 2018, 19(5): 1541.
|
| [26] |
Eyking A, Reis H, Frank M, et al. MiR-205 and MiR-373 are associated with aggressive human mucinous colorectal cancer [J]. PLoS One, 2016, 11(6): e0156871.
|
| [27] |
Korkmaz G, Horozoglu C, Arıkan S, et al. LGALS3 and AXIN1 gene variants playing role in the Wnt/ β-catenin signaling pathway are associated with mucinous component and tumor size in colorectal cancer [J]. Bosn J Basic Med Sci, 2016, 16(2): 108-113.
|
| [28] |
Jung YS, Wang W, Jun S, et al. Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via β-catenin [J]. Nat Cell Biol, 2018, 20(11): 1303-1314.
|
| [29] |
Li S, Peppelenbosch MP, Smits R. Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation [J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 74-79.
|
| [30] |
Kwon M, Rubio G, Nolan N, et al. FILIP1L loss is a driver of aggressive mucinous colorectal adenocarcinoma and mediates cytokinesis defects through PFDN1 [J]. Cancer Res, 2021, 81(21): 5523-5539.
|
| [31] |
Li X, Sun K, Liao X, et al. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component [J]. BMC Cancer, 2020, 20(1): 400.
|
| [32] |
Williams DS, Mouradov D, Newman MR, et al. Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation [J]. Mod Pathol, 2020, 33(7): 1420-1432.
|
| [33] |
Liu YY, Wen ZQ, Ma YR, et al. Application of T1-mapping combined with high-spatial-resolution T2-weighted imaging in discriminating mucinous from nonmucinous adenocarcinoma in rectal cancer [J]. Abdom Radiol (NY), 2025, 50(6): 2380-2387.
|
| [34] |
Horvat N, Hope TA, Pickhardt PJ, et al. Mucinous rectal cancer: concepts and imaging challenges [J]. Abdom Radiol (NY), 2019, 44(11): 3569-3580.
|
| [35] |
Shia J, McManus M, Guillem JG, et al. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy [J]. Am J Surg Pathol, 2011, 35(1): 127-134.
|
| [36] |
Cao W, Wu L, Zhao Y, et al. A new MRI-defined biomarker for rectal mucinous adenocarcinoma: mucin pool patterns in determining the efficacy of neoadjuvant therapy [J]. Front Oncol, 2020, 10: 1425.
|
| [37] |
Dos Anjos DA, Habr-Gama A, Vailati BB, et al. (18)F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypes [J]. Ann Nucl Med, 2016, 30(8): 513-517.
|
| [38] |
Queiroz MA, Naves A, Dreyer PR, et al. PET/MRI characterization of mucinous versus nonmucinous components of rectal adenocarcinoma: a comparison of tumor metabolism and cellularity [J]. AJR Am J Roentgenol, 2021, 216(2): 376-383.
|
| [39] |
Huang Q, Zou MH, Jiang Y, et al. Outcomes of laparoscopic surgery for mucinous colorectal adenocarcinoma [J]. J Laparoendosc Adv Surg Tech A, 2021, 31(6): 638-647.
|
| [40] |
Hendrick LE, Naffouje S, Imanirad I, et al. Incomplete resection is twice as likely in locally advanced mucinous compared to nonmucinous rectal adenocarcinoma: a national propensity-matched analysis [J]. J Surg Oncol, 2025, 131(6): 1090-1100.
|
| [41] |
Liao SW, Zhan JQ, Liu CT, et al. Survival benefit of primary tumor resection combined with chemotherapy in patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis [J]. Am J Clin Oncol, 2024, 47(1): 30-39.
|
| [42] |
Sun YW, Chi P, Lin HM, et al. Effect of neoadjuvant chemoradiotherapy on locally advanced rectal mucinous adenocarcinoma: a propensity score-matched study [J]. Gastroenterol Res Pract, 2017, 2017: 5715219.
|
| [43] |
Li B, Wu K, Li J, et al. Locally advanced rectal mucinous adenocarcinoma: is preoperative radiation necessary? [J]. J Gastrointest Oncol, 2022, 13(5): 2366-2374.
|
| [44] |
Schabl L, Duraes LC, Connelly T, et al. Does stage III rectal mucinous adenocarcinoma benefit from neoadjuvant chemoradiation?[J]. Tech Coloproctol, 2024, 28(1): 146.
|
| [45] |
刘山, 孟令新, 张可,等. FOLFOX和FOLFIRI方案用于大肠黏液腺癌辅助化疗的比较[J/CD]. 中华结直肠疾病电子杂志, 2016, 5(2): 159-162.
|
| [46] |
Yu D, Gao P, Song Y, et al. The differences on efficacy of oxaliplatin in locally advanced colon cancer between mucinous and nonmucinous adenocarcinoma [J]. Cancer Med, 2018, 7(3): 600-615.
|
| [47] |
Liao H, Tang C, Zhou Z, et al. Adjuvant radiotherapy is not necessary for stage III mucinous rectal cancer: evidence based on long survival analysis from seer data [J]. J Gastrointest Surg, 2023, 27(12): 2857-2866.
|
| [48] |
Guan X, Jia S, Chen W, et al. Long-term effect of radiotherapy in rectal cancer patients with mucinous tumor: a large population based study [J]. Sci Rep, 2017, 7: 43821.
|
| [49] |
Chen C, Chen X, Jiang J. Long-term effect of neoadjuvant radiotherapy in patients with locally advanced rectal mucinous adenocarcinoma: a population-based study of 1514 patients [J]. Sci Rep, 2023, 13(1): 11696.
|
| [50] |
Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer [J]. Ann Surg Oncol, 2008, 15(9): 2426-2432.
|
| [51] |
Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2021, 22(2): 256-266.
|
| [52] |
Smibert OC, Slavin MA, Teh B, et al. Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy [J]. Support Care Cancer, 2020, 28(6): 2745-2752.
|
| [53] |
Zhou YW, Long YX, Chen Y, et al. First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component [J]. Cancer Med, 2021, 10(10): 3388-3402.
|
| [54] |
Moretto R, Morano F, Ongaro E, et al. Lack of benefit from anti-EGFR treatment in RAS and BRAF wild-type metastatic colorectal cancer with mucinous histology or mucinous component [J]. Clin Colorectal Cancer, 2019, 18(2): 116-124.
|
| [55] |
Dilly A, Honick BD, Lee YJ, et al. Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors [J]. Cancer Med, 2020, 9(5): 1753-1767.
|
| [56] |
Kuracha MR, Govindarajan V, Loggie BW, et al. Pictilisib-induced resistance is mediated through FOXO1-dependent activation of receptor tyrosine kinases in mucinous colorectal adenocarcinoma Cells [J]. Int J Mol Sci, 2023, 24(15): 12331.
|
| [57] |
Ahmad R, Alam M, Hasegawa M, et al. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer [J]. Mol Cancer, 2017, 16(1): 33.
|
| [58] |
Kim JH, Park HE, Cho NY, et al. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers [J]. Br J Cancer, 2016, 115(4): 490-496.
|
| [59] |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 372(26): 2509-2520.
|
| [60] |
Diaz LA, Jr., Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study [J]. Lancet Oncol, 2022, 23(5): 659-670.
|
| [61] |
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with Nivolumab plus Ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer [J]. J Clin Oncol, 2018, 36(8): 773-779.
|
| [62] |
Fakih M, Wang C, Sandhu J, et al. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases [J]. Eur J Cancer, 2024, 196: 113437.
|
| [63] |
Baslan T, Hicks J. Unravelling biology and shifting paradigms in cancer with single-cell sequencing [J]. Nat Rev Cancer, 2017, 17(9): 557-569.
|
| [64] |
Hu FJ, Li YJ, Zhang L, et al. Single-cell profiling reveals differences between human classical adenocarcinoma and mucinous adenocarcinoma [J]. Commun Biol, 2023, 6(1): 85.
|
| [65] |
Chen Y, Hou W, Zhong M, et al. Comprehensive proteomic analysis of colon cancer tissue revealed the reason for the worse prognosis of right-sided colon cancer and mucinous colon cancer at the protein level [J]. Curr Oncol, 2021, 28(5): 3554-3572.
|
| [66] |
Xu K, Zheng S, Li B, et al. Molecular characterization of colorectal mucinous adenocarcinoma and adenocarcinoma, not otherwise specified, identified by multiomic data analysis [J]. Front Mol Biosci, 2023, 10: 1150362.
|
| [67] |
Zhou H, Shen Y, Zheng G, et al. Integrating single-cell and spatial analysis reveals MUC1-mediated cellular crosstalk in mucinous colorectal adenocarcinoma [J]. Clin Transl Med, 2024, 14(5): e1701.
|
| [68] |
Aydin İC, Torun M, Sönmez MR, et al. The influence of mucinous histology on the prognosis of stage II and III colorectal cancers [J]. Medicina (Kaunas), 2025, 61(3): 456.
|
| [69] |
Wang X, Wang H, He H, et al. Clinicopathological and prognostic features of colorectal mucinous adenocarcinomas: a systematic review and meta-analysis [J]. BMC Cancer, 2024, 24(1): 1161.
|
| [70] |
Kim S, Huh JW, Lee WY, et al. Prognostic impact of mucinous adenocarcinoma in stage II and III colon cancer [J]. Dis Colon Rectum, 2023, 66(11): 1473-1480.
|
| [71] |
Wang L, Hirano Y, Heng G, et al. Mucinous adenocarcinoma as a high-risk factor in stage II colorectal cancer: a propensity score-matched study from Japan [J]. Anticancer Res, 2020, 40(3): 1651-1659.
|
| [72] |
Li J, Yang L, Bai F, et al. Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component [J]. Future Oncol, 2021, 17(11): 1351-1362.
|
| [73] |
Yan C, Yang H, Chen L, et al. Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study [J]. BMC Cancer, 2021, 21(1): 1286.
|
| [74] |
Catalano V, Loupakis F, Graziano F, et al. Prognosis of mucinous histology for patients with radically resected stage Ⅱ and Ⅲ colon cancer [J]. Ann Oncol, 2012, 23(1): 135-141.
|
| [75] |
Wang P, Song Q, Lu M, et al. Establishment and validation of a postoperative predictive model for patients with colorectal mucinous adenocarcinoma [J]. World J Surg Oncol, 2022, 20(1): 330.
|
| [76] |
Ma Y, Luo Y, Lin N, et al. Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma [J]. Onco Targets Ther, 2018, 11: 3659-3670.
|
| [77] |
Sun Y, Deng Y, Xu M, et al. A refined prediction of early recurrence combining tumor deposits in patients with resected rectal mucinous adenocarcinoma [J]. Surg Today, 2023, 53(7): 762-772.
|
| [78] |
Sun Y, Huang Z, Chi P. An inflammation index-based prediction of treatment response to neoadjuvant chemoradiotherapy for rectal mucinous adenocarcinoma [J]. Int J Clin Oncol, 2020, 25(7): 1299-1307.
|
| [79] |
Liao YC, Fu M, Wang XF, et al. Combined fibrinogen-to-pre-albumin ratio and carbohydrate antigen 19-9 score is a promising metric to predict progression of metastatic colorectal mucinous adenocarcinoma [J]. J Clin Lab Anal, 2021, 35(5): e23757.
|